Septerna (NASDAQ:SEPN) Sets New 52-Week Low – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) hit a new 52-week low during mid-day trading on Saturday . The company traded as low as $17.71 and last traded at $17.99, with a volume of 207078 shares trading hands. The stock had previously closed at $20.85.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target for the company. Wells Fargo & Company began coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective for the company. Finally, TD Cowen began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Stock Down 13.7 %

The company’s 50-day simple moving average is $23.63.

Insider Buying and Selling at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This represents a 6.34 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.